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Background: Ibuprofen, diclofenac and aspirin belong to the same class of drugs called NSAIDs, but 
are used interchangeably at Tonga Hospital. The problem with this approach is that it may lead to 
preventable misguided and increased spending on pharmaceuticals.  
Aim: To investigate the pharmacoeconomic implications of interchangeable use of oral NSAIDs for 
pain management at a district hospital.  
Setting: This study was conducted at a district hospital in the Tonga village in the Nkomazi 
municipality, Mpumalanga Province, South Africa. 
Methods: A quantitative retrospective descriptive study, using existing patient records as well as 
medicine stock control records, was conducted to investigate the cost-effectiveness of oral NSAIDs 
when used interchangeably in the management of pain in adult patients at a district hospital. 
Results: The total number of patients included in this study was 211 in a split of 104 in 2013 and 107 
in 2014. The mean ages of all the patients who participated in our study in 2013 and 2014 were 36 and 
35 years respectively and there were more females than males. Most patients who presented at Tonga 
Hospital for pain management were suffering from minor bodily/joint pains (36.0%, n=76), whereas 
the least number of patients were suffering from bone fractures (10.9%, n=23). Our study found that 
most patients (31.3%; n=66) treated with ibuprofen were suffering from minor bodily/joint pains, 
whereas the least number of patients (1.4%; n=3) treated with diclofenac were suffering from 
inflammatory conditions. Females were the largest users of NSAIDs (both ibuprofen and diclofenac) 
in Tonga Hospital when compared with males. Patients between the ages of 19-35 years were the 
most prevalent (28.4%, n=60) who were treated with ibuprofen when compared with patients 18 years 
and below (9.5%, n=20). Also, patients who were 18 years and younger and treated with diclofenac 
were the least number of patients (1.4%, n=3). The highest total NSAID stock volumes issued from 
July to December of 2013 and 2014 combined was ibuprofen (36978 packs) when compared with 
diclofenac (11127 packs). The stock volumes for both ibuprofen and diclofenac were higher in July, 
with 8170 for Ibuprofen and 2099 for diclofenac. Diclofenac stock volumes fell to their lowest (1583) 




stock volumes issued might be attributable to many factors including but not limited to non-delivery 
by the supplier or non-ordering by the pharmacy staff. In all instances ibuprofen stock volumes issued 
were higher than that of diclofenac. The acquisition cost of ibuprofen when calculated as mean price 
per tablet during 2013 to 2014 was consistently lower, with an average price of (0.285 ZAR) when 
compared with diclofenac (0.995 ZAR). 0.3% of the population of Nkomazi east, on average, gets 
treatment of ibuprofen daily whereas 0.01% of the population gets treatment of diclofenac daily. The 
mean cost per defined daily dose was consistently lower for ibuprofen in both 2013 (0.84 ZAR) and 
2014 (0.87 ZAR) when compared with diclofenac in 2013 (2.94 ZAR) and 2014 (3.03 ZAR). The 
sensitivity analysis points in favour of ibuprofen over diclofenac as indicated when increasing or 
decreasing the mean price per tablet by 50% of either ibuprofen or diclofenac.  
Conclusion: This study found that the acquisition costs of NSAIDs in relation to the mean price per 
pack of oral tablets had been consistently higher for diclofenac than they were for ibuprofen in Tonga 
Hospital. Therefore, the use of ibuprofen oral tablets in the management of pain at a district hospital is 
cost-effective when compared with diclofenac oral tablets. 
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INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
The Tonga Hospital was opened in 1999. It is situated in the Tonga village in the Nkomazi 
municipality, Mpumalanga Province, South Africa. It has fourteen feeder primary health care centres, 
many of which are rural farming communities that are isolated and sparsely populated. Most health-
care services are provided through mobile services. The hospital has a catchment population of about 
393 030 (Census, 2011:42) and is a 143-bed district hospital (Chu et al., 2011:154) with a capacity for 
around 250 beds (Government gazette 35101, 2012:22). On average the Tonga Hospital treats about 
5936 patients per month of combined in-patients and out-patients (DHIS, 2015). The cost per head of 
patients is about R1481.50 per day as at year 2010 (Chu et al., 2011:155). A considerable number of 
patients who visit the Tonga Hospital come from two neighbouring countries, Mozambique and 
Swaziland in search of better economic opportunities and health care. Only a small number of patients 
come from Zimbabwe and other Provinces or municipalities.  
 
When the hospital management makes budget forecasts, the budget inputs do not take into account the 
extra number of patients who flock from outside the Tonga Hospital catchment area as numbers 
cannot be accurately quantified. These foreign patients have to be given treatment once they present 
to the facility. “A country’s difficult financial situation does not absolve it from having to take action 
to realize the right to health” (World Health Organization, 2008:5). Tonga Hospital offers the 
following services among others: family medicine and primary health care, dental, pharmacy, trauma, 
rehabilitation, medicine, surgery, obstetrics, paediatrics, psychiatry, eye care, geriatrics, abuse victim 
empowerment, voluntary counselling and testing, male medical-circumcision. 
 
Unemployment rate stands at about 34.3% at Nkomazi (Census, 2011:68). This means that the local 
community depends almost entirely on the state health care centres for its health care needs. This 
community has a low socio-economic status, thus Tonga Hospital forms the back-bone of its health 
care needs. This emphasizes the importance of the hospital being able to cater for a large number of 
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patients. This means that this hospital must be financially sound and be able to properly manage the 
appropriation of funds for health programs. In order to meet the health care needs of the community, 
Tonga Hospital management is always faced with the decision to allocate funds to health programs of 
which amongst others is medicines availability. Medicines are expensive and their prices continue to 
increase on a yearly basis. “South Africa has implemented a number of important medicine pricing 
interventions in the post-apartheid era, informed by the 1996 National Drug Policy” (Gray et al., 
2015). The South African government controls medicine prices through the Medicines and Related 
Substances Act (101/1965) by way of the single exit price at the National Department of Health 
(National Department of Health, 2015).  
 
In the Mpumalanga Province in particular, the health budget had risen from R8.084 billion in the 
2013/2014 fiscal year to R8.9 billion in 2014/2015 fiscal year (Mpumalanga Department of Finance, 
2015). Unfortunately, the budget allocation was reduced in 2015/16 to R7.317 billion due to National 
Treasury budget allocation cuts (Mpumalanga Department of Finance, 2015),  partly due to South 
Africa’s shrinking fiscal budget and because of the “continued weakness in the global economy and 
domestic structural constraints” (African Economic Outlook, 2015). Medicines form part of the 
category ‘goods and services’ when the Mpumalanga Provincial Health budget is distributed among 
different health programs. A large portion of the budget is mostly directed to medicines procurement. 
To make things worse the reduced budget in the 2015/2016 financial year meant that medicine 
procurement budget allocation would also reduce. At this, the MEC for Mpumalanga Provincial 
Health issued the following stern advice: “the tight fiscal environment demands prudency in 
allocations, efficiencies in the utilisation of resources and slowing down of spending on non-critical 
activities” (Mpumalanga Department of Finance, 2015). Weinstein et al. reiterated this by saying 
“limits on health-care resources mandate that resource-allocation decisions be guided by 
considerations of cost in relation to expected benefits” (Weinstein et al., 1977).  
 
One of the objectives of the SA’s National Drug Policy, is “to promote the cost-effective and rational 
use of drugs, as well as to optimize the use of scarce resources. The health objective of the NDP is to 
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ensure the availability and accessibility of essential drugs to all citizens. The NDP emphasizes the fact 
that drug procurement and distribution should be limited to drugs on the list of Essential drugs” 
(National Drug Policy, 1996:11).  Therefore, it is imperative that all health care professionals put in 
place measures to cut costs while delivering quality healthcare service for all. 
The availability of oral non-steroidal anti-inflammatory drugs (NSAIDs) for adult patients at Tonga 
Hospital is limited to Diclofenac, Ibuprofen, and Aspirin. These NSAIDs are only available in the 
following strengths and pack sizes: Diclofenac 50mg with a pack size of 21 tablets, Ibuprofen 
200mg with a pack size of 15 tablets and Ibuprofen 400mg with a pack size of 28 tablets, and 
Aspirin 300mg with a pack size of 14 tablets. These NSAIDs are also listed in the National 
Essential Medicines List (NEML) (Standard Treatment Guidelines and Essential Drugs List, 2012: 
Chapter 13-14). The NEML is a national medicine formulary that can be used by Pharmacy and 
Therapeutics Committees (PTCs) in the public sector as a guide in crafting local medicines 
formularies. ‘’Using an essential medicines list (EML) makes medicine management easier in all 
respects; procurement, storage and distribution are easier with fewer items, and prescribing and 
dispensing are easier for professionals if they have to know about fewer items” (World Health 
Organization 2002 :3). 
 
The afore-mentioned NSAIDs have all been listed in the Tonga Hospital formulary for the 
management of adult patients with minor to moderate pain. The inclusion of all these NSAIDs in the 
local formulary means that they had been rated as essential for Tonga Hospital. ‘’The World Health 
Organization (WHO) describes essential medicines as those that satisfy the priority health care needs 
of the population. Essential medicines are intended to be available within the context of functioning 
health systems at all times in adequate quantities, in the appropriate dosage forms, with assured 
quality and adequate information, and at a price the individual and the community can afford” 
(Standard Treatment Guidelines and Essential Drugs List, 2012: XV).  
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As per the South African NDP (1996) 
When two or more drugs are equivalent, preference would be given to those which have: 
the best cost advantage; best pharmacokinetic properties; has been the best researched; 
the best patient compliance; and the most reliable local manufacturer. If two or more 
medicine items belong to the same class and produce similar outcomes as would be 
demonstrated in chapter 2 with ibuprofen and diclofenac oral tablets, it may not be 
appropriate to list all of them in a formulary especially in the face of budgetary 
constraints. Despite the many other cost-containment measures which are implemented 
every financial year, medicine expenditure at Tonga Hospital remains high and continues 
to grow. (National Drug Policy for South Africa, 1996:11).   
 
The Tonga Hospital PTC is expected to play an essential role in addressing rational use of medicines 
in the hospital to ascertain that medicine expenditure is always kept under control. It is also is well-
placed as a structure in the hospital to implement systems that promote rational use of medicines.  
 
Health programs should be funded equitably through prioritization. Medicines are one of the priorities 
amongst health programs that require funding. This is affirmed by the National Health Minister’s six 
priorities. “The economic impact of pharmaceuticals is substantial. Spending on pharmaceuticals 
represents 15 to 30% of health spending in transitional economies and 25 to 66% in developing 
countries. In most low income countries pharmaceuticals are the largest public expenditure on health 
after personnel costs and the largest household health expenditure” (Agrawal et al., 2013). If 
medicines would always be allowed to take a huge portion of the budget, it would mean that other 
programs would have their progress stifled due to lack of funds. Also, if one medicine item would be 
allowed to take a large portion of the budget allocation, it would mean that other life-saving medicines 
would not be procured due to budget deficit. Therefore, any act of funds misappropriation has a 
negative impact on the number of patients needing to access a particular health program.  
 
 
Chapter 1: Introduction and Literature Review 
6 
 
If targeted strategies of controlling medicine expenditure can be properly applied through the 
concept of cost-containment, it would help Tonga Hospital to treat more patients with the same 
budget allocation. According to section 38 of Public Finance Management Act it is considered 
fruitless or wasteful expenditure when resources are not used efficiently, this includes medicines 
budget (1999). This means that cost-effectiveness should be incorporated into the design of any 
health care strategy for Tonga Hospital, which includes medicines procurement, storage, and supply.  
 
1.1.1 Significance 
This study sought to encourage review of the existing medicine formulary at Tonga Hospital whereby 
the NSAID that would be lowest in cost or deemed cost-effective would be preferred for inclusion in 
the reviewed hospital formulary. The NSAID with higher costs, and or fewer benefits, would be 
omitted in the new formulary. Emphasis was placed on the value for money in the face of limited 
financial resource. The ultimate goal would be to reduce costs associated with medicine expenditure. 
 
1.1.2 The research problem 
Ibuprofen, diclofenac, and aspirin belong to the same class of drugs called NSAIDs, but are used 
interchangeably at Tonga Hospital. This hospital does not have unlimited resources, which include 
medicine storage space, finance, and human resource capacity. If medicine storage space is not 
managed properly due to the stock volumes of one medicine item being excessively higher than 
necessary, that would lead to unavailability of other essential medicine items. If the limited hospital 
budget is used to finance similar medicine items that have same clinical outcomes, this would mean 
that there would be less funding available for other essential medicines. It would also require more 
staff members to manage the cumulative stock volumes of each of the NSAIDs, in this way it would 
mean more costs in the form of salaries. It is therefore of paramount importance that the contributing 
factors to high medicine expenditure in the hospital be kept in check, including avoiding duplication 
of medicine items in the hospital formulary. This study investigated the cost-effectiveness when 
Ibuprofen, Diclofenac, and Aspirin are used interchangeably by the same health care facility. 
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1.2 Literature Review 
 
1.2.1 Economic burden of pain management and the benefit of budget rationalization 
“Pain represents a major clinical, social and economic problem, with estimates of its prevalence 
ranging from 8 to over 60%. The impact of pain on economies is enormous, with the cost of back pain 
alone equivalent to more than a fifth of one country's total health expenditure and 1.5% of its annual 
gross domestic product, while in another, it represents three-times the total cost of all types of cancer. 
The burden that pain imposes on individuals and the enormous costs that society has to bear as a 
result clearly demonstrate the need for collective thinking in the decision-making process. A broad, 
strategic perspective – based on evidence relating to effectiveness (including tolerability), efficiency 
and equity – is required in determining issues relating to the provision of services and resource 
allocation” (Phillips, 2006).  
In most settings, the model of acute pain treatment, with its emphasis on pharmacological therapy, is 
used for acute and chronic pain alike. Persistent chronic pain, however, often leads to complex social 
and psychological maladaptations, as well as substantial direct and indirect costs. Thus, the proper 
treatment of chronic pain usually involves pharmacological, behavioural and psychological 
interventions. Pain is a subjective sensation, but persistent chronic pain often results in long term 
neurophysiological and psychological changes that might be more appropriately considered disease 
manifestations. The costs and outcomes of various treatment strategies vary considerably and there is 
a need for comparative studies (Zagari et al., 1996). 
However, it should be noted that more does not necessarily mean better health care, and diverting 
additional resources into health care facilities and services will not automatically generate 
improvement in the health of the population. Up to 25% of all health care services provided may be 
unnecessary (Phillips 2008, Chapter1: 2-3).  
In assessing the direct costs of pain management, it is conventional to categorize the components. For 
example, a German study estimated that the cost of back pain accounted to US$5 billion each year, 
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with 22 percent of costs accounted for by medication. It is essential that policy makers are fully aware 
of all aspects associated with the costs of pain and its management. One such example of this limited 
economic perspective in pain management is the iatrogenic costs associated with NSAIDs, which 
often result in costly side effects. These iatrogenic costs have been estimated at between US$58 and 
US$127 for each patient prescribed an NSAID in the UK. Estimates of the economic burden 
associated with pain fail to do justice to the extent of suffering and reduced quality of life experienced 
by patients and warrants pain relief being regarded as a universal human right (Phillips 2008, Chapter 
6:77).  
Pharmaceutical prescribing currently represents around 10 percent of total National Health Service in 
South Africa expenditure, and is one of the most inflationary elements of spending. Pharmaceuticals 
are one of the most commonly used and important interventions available to doctors in clinical 
practice, and their appropriate use can reduce mortality, morbidity and costs falling on other parts of 
the health care system. In other countries, particularly Australia and Canada, policies have been 
introduced to limit the introduction of new drugs to those which demonstrate cost-effectiveness. 
Evidence of effectiveness and cost-effectiveness, when it exists, is not always used. In the hospital 
sector, formularies and treatment protocols may encourage cost-effective prescribing, by limiting the 
use of certain medicines or outlining their appropriate use, although cost-effectiveness is not normally 
a major criterion in formulary or protocol development. Economic evaluation assesses the costs and 
consequences of alternative health care treatments and programmes; a drug therapy may be compared 
with an alternative, which may be another drug, surgery, or doing nothing (Maynard, et al. n.d).  
Prioritisation and streamlining of strategic health programmes at facility level can have cumulative 
effect on cost-minimisation in the health system. For example, if a particular treatment strategy were 
found to yield little health gain relative to the resources used, then it could be advantageous to re-
deploy resources to other activities that yield greater health gain (National Collaborating Centre for 
Primary Care, 2009). Indeed, the facilities at district hospital levels must promote cheaper generic 
drugs to patients – and help contain medical inflation (Bateman & Chris, 2014).  
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According to Bloor, et al. (1996) the assessments of ‘cost-effectiveness’ consider more than just 
comparative costs. Therefore the most cost-effective therapy is not necessarily the cheapest; it 
depends on whether the additional health status gained from a more expensive therapy justifies the 
extra cost (cost-benefit analysis). Assessments of comparative costs are not restricted to the costs of 
the medicines themselves; they may also include the costs of drug administration and the costs of 
treating side-effects (Bloor, et al., 1996). 
 
1.2.2 Chemical classification of Ibuprofen, Diclofenac, and Aspirin 
Ibuprofen, Diclofenac, and Aspirin belong to the same class of NSADs but each has a different 
chemical structure. That may account for their differences in NSAIDs safety and perhaps acquisition 
costs.  
 
1.2.3 Pharmacokinetic properties  
The following aspects will be analysed for superior pharmacokinetic properties of the NSAIDs under 
study: absorption, plasma proteins binding, half-life, and elimination. 
   
1.2.3.1 Diclofenac 
Oral absorption is rapid and near-complete when administered in the form of sugar-coated tablets, and 
slower when administered as enteric-coated tablets, particularly when taken together with food. At 
therapeutic concentrations, diclofenac is more than 99% bound to plasma proteins. Its terminal half-
life in plasma is approximately 1-2 hours (Geller et al., 2010). Diclofenac is predominantly eliminated 
via hepatic biotransformation with less than 1% of the dose being excreted unchanged via the kidneys 
(Kirchheiner et al., 2003). And Bort et al. (1999) suggest that this reaction may be implicated in the 
hepatotoxicity of diclofenac.  
 
1.2.3.2 Ibuprofen 
The absorption of ibuprofen is rapid and complete when given orally (Davies & Neal, 1998). 
Ibuprofen is more strongly bound to normal plasma proteins (Davies & Neal, 1998). Like other 
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NSAIDs, ibuprofen is extensively metabolised in the liver (Pozzi et al., 2011).  Ibuprofen is 
eliminated following biotransformation to glucuronide conjugate metabolites that are excreted in 
urine, with little of the drug being eliminated unchanged (Davies & Neal, 1998). Ibuprofen has a 
serum half-life of 1.8 to 2 hours (Bushra et al., 2010). Ibuprofen blocks both the COX-1 and the 
COX-2 enzymes, but has been shown to be safe and cost-effective with a highly effective analgesic 
and anti-inflammatory action in post-endodontic pain (Pozzi et al., 2011). 
 
1.2.3.3 Aspirin 
After oral administration as an aqueous solution aspirin is rapidly absorbed at the low pH of the 
stomach millieu. Less rapid absorption is observed with other formulations due to the rate limiting 
step of tablet disintegration - this latter factor being maximal in alkaline pH. The rate of aspirin 
absorption is dependent not only on the formulation but also on the rate of gastric emptying. Both 
aspirin and salicylic acid are bound to serum albumin (aspirin being capable of irreversibly 
acetylating many proteins), and both are distributed in the synovial cavity, central nervous system, 
and saliva. The serum half-life of aspirin is approximately 20 minutes. Salicylic acid is renally 
excreted in part unchanged and the rate of elimination is influenced by urinary pH, the presence of 
organic acids, and the urinary flow rate (Needs et al., 1985).  
 
1.2.4 Pharmacodynamic properties of NSAIDs 
The cyclo-oxygenase-1 (COX-1) and COX-2 enzymes produce prostaglandins following the 
metabolism of omega-6 polyunsaturated fatty acid (arachidonic acid). Prostaglandins are chemical 
messengers that mediate inflammation, fever and the sensation of pain (Day et al., 2013). NSAIDs 
exert their therapeutic characteristics by inhibiting the production of prostaglandins by means of 
cyclooxygenase inhibition, particularly isoenzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-
2 (COX-2), which have been shown to catalyse the formation of prostaglandins in the arachidonic 
acid pathway1, 2. COX-1 is normally found in platelets, vascular endothelial cells, the stomach and 
kidneys, where it is involved in the production of prostaglandins that are responsible for the protection 
of the stomach wall (PGE2), platelet aggregation (TXA2) and kidney function (Geller et al., 2010). 
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The ratio of inhibition of COX-1 to COX-2 by NSAIDs determines the likelihood of adverse effects 
(Cashman, 1996). The beneficial actions of nonsteroidal anti-inflammatory drugs (NSAIDs) have 
been linked to their ability to inhibit inducible COX-2 at sites of inflammation, and their side effects 
(e.g., gastric damage) to inhibition of constitutive COX-1 (Warner et al. 2004). Ibuprofen inhibits 
almost completely COX-1 activity after single and repeated intake whereas COX-2 inhibition average 
80% at corresponding times. Diclofenac reduced COX-1 activity by about 70% and COX-2 by about 
96% whatever treatment duration (Blain et al., 2002).  
 
Low-dose aspirin (≤100 mg daily) irreversibly inhibits platelet COX-1 activity by acetylating the 
serine-529 residue, resulting in > 95% inhibition of thromboxane A2 (TXA2) production and thus 
inhibition of TXA2-mediated platelet aggregation throughout the 24-hour dosing interval. Once COX-
1 has been acetylated by aspirin, the substrate cannot gain access to the catalytic site of the enzyme 
for the lifetime of the platelet, so that upon aspirin withdrawal, restoration of TXA2 biosynthesis is a 
linear function of platelet turnover (Baigent et al., 2003). This unique action probably explains why 
aspirin is so efficient in preventing arterial thrombotic events; randomized trials indicate that low-dose 
aspirin reduces the risk of vascular events (myocardial infarction, stroke, or vascular death) by 
approximately one-fourth in a wide range of high-risk patients (Baigent et al.). Aspirin also inhibits 
COX-1 in the gastric and duodenal mucosa, as a function of the dose level and dosing interval, 
resulting in a reduction in PGE2-mediated cytoprotection against the acid milieu (Baigent et al., 
2003).  
 
Non-selective NSAIDs were associated with similar increased risks of serious gastrointestinal events, 
and all but naproxen were associated with similar increased risk of serious cardiovascular events, but 
the partially selective NSAID, nabumetone was gastroprotective compared with nonselective NSAIDs 
(Peterson et al., 2006). COX-2 selective NSAIDs significantly reduced symptomatic ulcers compared 
with placebo (RR 0.41, 95% CI: 0.3, 0.7). COX-2 specific NSAIDs appeared to significantly reduce 
serious gastrointestinal complications (RR 0.55, 95% CI: 0.4, 0.8) and symptomatic ulcers (RR 0.49, 
95% CI: 0.4, 0.6) (Hooper et al., 2004).  
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1.2.4.1 Cardiovascular Risk 
Short-term and long-term use of NSAIDs is associated with increased cardiovascular risk (Olsen et 
al., 2011). Listing of NSAIDs on national EMLs should take account of cardiovascular risk, with 
preference given to low risk drugs (McGettigan et al., 2013). NSAIDs rated by relative risk for 
cardiovascular events (in ascending order): Naproxen < Celecoxib < Piroxicam < Ibuprofen < 
Meloxicam < Indomethacin < Diclofenac < Rofecoxib (at doses more than 25 mg). Diclofenac has a 
risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular 
toxicity. Diclofenac should be removed from EMLs (ibid). Extensive use of diclofenac, similarly to 
rofecoxib and celecoxib, substantially increases the risk of acute myocardial infarction. There is little 
suggestion of such an effect in users of ibuprofen (Jick et al., 2007). Aspirin reduces the risk of first 
Myocardial Infarction. The benefits of long-term aspirin therapy are likely to outweigh any risks 
(Eidelman et al., 2003). Cardiovascular risk needs to be taken into consideration when prescribing any 
non-steroidal anti-inflammatory drug (Trelle et al., 2011). 
 
1.2.4.2 Gastrointestinal risks 
Although effective in the treatment of pain associated with rheumatic conditions such as osteoarthritis 
and rheumatoid arthritis, long-term use of NSAIDs is primarily limited by their association with upper 
gastrointestinal (GI) toxicity. Adverse effects range from dyspepsia and abdominal pain to ulceration 
and bleeding. GI damage elicited by NSAIDs arises as the result of biochemically induced topical 
irritant effects and by topical and systemic pharmacological suppression of gastroprotective 
prostaglandins. Variation in the physicochemical properties and pharmacological profiles among the 
individual NSAIDs translate into inter-agent differences regarding propensity to cause adverse GI 
effects (Bannwarth et al., 2008). A study conducted by Castellsague et al. (2013) found that the 
relative risk with regards to gastrointestinal risk of ibuprofen and diclofenac was 2 to <5. Levy et al. 
(1974) also alluded to the fact that Ibuprofen has the lowest gastrointestinal risk among NSAIDs, 
while diclofenac has intermediate risks.  
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In a systemic review Henry et al. (1996) found that the use of low risk drugs such as ibuprofen in low 
dosage as first line treatment would substantially reduce the morbidity and mortality due to serious 
gastrointestinal toxicity from these drugs. According to Lugardon et al. (2004) the reported risk of 
gastrointestinal events was low among patients treated with ibuprofen, compared with diclofenac and 
other NSAIDs. Lower rates of occurrence of GI complications in patients treated with ibuprofen could 
be attributed to its short half-life, about 2 hours (Pozzi et al., 2011).  
According to Day et al. (2013) the risk factors for gastrointestinal adverse effects associated with 
NSAID use include: 
• Age over 65 years 
• Previous adverse reaction to NSAIDs 
• The use of other medicines that may exacerbate any gastrointestinal adverse effects, e.g. 
anticoagulants, selective serotonin reuptake inhibitors (SSRIs) and corticosteroids 
• Liver disease 
• Chronic kidney disease (CKD) 
• Smoking 
1.2.4.3 Hepatotoxicity during NSAID treatment 
NSAIDs have been associated with idiosyncratic hepatotoxicity in susceptible patients (Boelsterli et 
al., 2002). The percentage of patients with liver toxicity during NSAID treatment is very low during 
treatment with ibuprofen versus diclofenac (Pozzi et al., 2011).  
 
1.2.4.4 Nephrotoxicity during NSAID treatment 
The use of NSAIDs is associated with risk of acute kidney injury (AKI). In a study conducted by 
Lafrance et al. (2009), it was demonstrated that the risk of AKI may vary among different 
NSAIDs with risk generally increasing with decrease in selectivity, for example it was found that 
diclofenac is more selective than ibuprofen. In this way, diclofenac may be a little safer to the kidney 
when compared with Ibuprofen.  
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1.2.4.5 NSAIDs use and hypersensitivity 
NSAIDs hypersensitivity is characterised by symptoms ranging in speed of onset from anaphylaxis 
and bronchospasm to delayed skin and systemic reactions occurring over weeks (Kowalski et al., 
2011). The reaction is due to COX-1 inhibition and is not mediated by IgE, therefore it is not a true 
allergy (Kowalski et al.). Aspirin may trigger respiratory reactions known as Aspirin-Exacerbated 
Respiratory Disease (Lee et al., 2011). People with asthma are at a higher risk for experiencing 
serious allergic reaction (Lee et al). 
 
1.2.4.6 NSAIDs and Pregnancy 
The significant association between diclofenac and ibuprofen use late in pregnancy, and maternal 
bleeding and asthma in the child, respectively, is consistent with their pharmacological effects 
(Nezvalová et al., 2013). Ibuprofen does not seem to increase global malformation risk but NSAID 
use in late pregnancy remains a concern (Damase-Michel et al., 2014). The current literature suggests 
that the use of low-dose aspirin during pregnancy is safe with regard to congenital anomalies and 
fetal, neonatal, and maternal cardiovascular physiologic state and haemostasis (Dekker et al., 1993). 
 
1.2.4.7 Common non-communicable Conditions that can be managed with NSAIDs 
There is no cure for inflammatory arthritis at present, so the treatments aim to relieve pain and 
stiffness and improve your ability to move. NSAIDs such as aspirin, ibuprofen, diclofenac and 
cyclo‐oxygenase‐2 inhibitors or COX‐2s (for example celecoxib), are used to decrease pain and 
swelling (Colebatch et al., 2011). 
 
NSAIDs are indicated for the symptomatic treatment of the following conditions (Standard Treatment 
Guidelines and Essential Drugs List, 2012): 
• Rheumatoid arthritis. NSAIDs are particularly useful in the inflammatory forms of arthritis 
(such as rheumatoid arthritis) and, sometimes, in the more severe forms of osteoarthritis. 
• Osteoarthritis 
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• Acute gout 
• Inflammatory arthropathies: ankylosing spondylitis, psoriatic arthritis, Reiter's syndrome 
• Dysmenorrhoea (painful menstruation), menstrual cramps 
• Headache and migraine 
• Postoperative pain  
• Mild-to-moderate pain due to inflammation and tissue injury  
• Back pain and sciatica 
• Sports injuries, sprains, and strains 
• Dental pain 
• Pain from kidney stones (renal colic) 
• Reduction of fever 
• Prevention of blood clotting (Aspirin only) 
1.3 The purpose of the study 
The purpose of the study was to determine whether the use of oral NSAIDs interchangeably in the 
management of pain in adult patients at Tonga Hospital is cost-effective. The results of the study 
would be used by the Hospital Pharmacy and Therapeutics Committee (HPTC) and Hospital 
Management to inform their decision-making when designing hospital medicines formulary.   
 
1.4 The objectives of the study 
This retrospective study investigated the cost-effectiveness of oral NSAIDs when used in the 
management of pain in adult patients at Tonga Hospital. 
 
The study was designed:  
q To determine whether interchangeable use of each of the oral NSAIDs under study in the 
management of pain in adult patients at Tonga Hospital is cost-effective. 
q To identify prescriber patterns or preferences between each of the oral NSAIDs under study 
in the management of pain in adult patients at Tonga Hospital 
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1.5 The research questions 
q What is the average acquisition cost of each of the oral NSAIDs under study at Tonga 
Hospital? 
q What is the average stock volume of each of the oral NSAIDs under study in regards to 
storage space requirements at Tonga Hospital? 
q What are patterns of prescribing each of the oral NSAIDs under study when used in the 
management of pain in adult patients at Tonga Hospital? 
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Background: Ibuprofen, diclofenac and aspirin belong to the same class of drugs called NSAIDs, 
but are used interchangeably at Tonga Hospital. The problem with this approach of NSAIDs use is 
that it may present with preventable misguided and increased spending on pharmaceuticals.  
Aim: To investigate the pharmacoeconomic implications of interchangeable use of oral NSAIDs for 
pain management at a district hospital.  
Methods: This descriptive retrospective study used existing patient records as well as medicine stock 
control records to investigate the cost-effectiveness of oral NSAIDs when used interchangeably in the 
management of pain and inflammatory conditions in adult patients at a district hospital. 
Results: A total of 211 (104 in 2013 and 107 in 2014) patients were included in this study. The mean 
age of participants in 2013 and 2014 was (36 ± 1,48) and (35 ± 1,49) years respectively and there 
were more females than males. Most patients who presented at Tonga Hospital for pain management 
were suffering from minor bodily/joint pains (36.0%, n=76), whereas the least patients were suffering 
from bone fractures (10.9%, n=23). Our study found that most patients (31.3%; n=66) who were 
treated with ibuprofen were suffering from minor bodily/joint pains. The acquisition cost of ibuprofen 
when calculated as mean-price-per-tablet during 2013 to 2014 was consistently lower, with an 
average price of (0.285 ZAR) when compared with diclofenac (0.995 ZAR). The mean cost per 
defined daily dose (DDD) was consistently lower for ibuprofen in both 2013 (0.84 ZAR) and 2014 
(0.87 ZAR) when compared with diclofenac in 2013 (2.94 ZAR) and 2014 (3.03 ZAR).  
Conclusion: The sensitivity analysis points in favour of ibuprofen over diclofenac as indicated when 
increasing or decreasing the mean price per tablet by 50% of either ibuprofen or diclofenac. 
Therefore, the use of ibuprofen oral tablets in the management of pain at a district hospital is cost-








Nonsteroidal anti-inflammatory drugs (NSAIDs) play a vital role in the management of acute and 
chronic pain. The NSAIDs such as ibuprofen, diclofenac, and aspirin exert their therapeutic actions by 
inhibiting cyclooxygenase-1 and cyclooxygenase-2 (Geller et al., 2010). These drugs are used 
interchangeably at the Tonga Hospital because they belong to the same class of drugs used for the 
management of pain. However, the differences in terms of the costs of each of these medications often 
present many pharmacoeconomic implications for the health care professional and for the 
government.  
 
It cannot be disputed, however, that management of pain and inflammation represents a major 
clinical, social and economic burden globally (Phillips, 2006). The costs and outcomes of various 
treatment strategies vary considerably and there is always a need for comparative studies (Zagari et al. 
1996). Also, frequent use of NSAIDs is associated with “iatrogenic costs”, which often result from 
costly side effects (Phillips, 2008). Also, the chronic use of NSAIDs is associated with serious risks 
that may at times warrant hospitalization, for example, Rainsford & Velo indicated that 
hospitalizations as a result of renal impairment occur more frequently among NSAID users than 
would be expected among non-users in the same age-sex group (Rainsford & Velo 2012:373). 
However, not all NSAIDs are the same, as reported by Levy & Micha that “ibuprofen has the lowest 
gastrointestinal risk among NSAIDs, while diclofenac has intermediate risks” (Levy & Micha, 1974). 
Therefore, many patients who present with pain at a hospital may also be having other chronic 
conditions such as hypertension, retroviral disease, diabetes mellitus, etc. For example, some patients 
who are on anti-retro viral (ARVs) drugs may not benefit from NSAIDs use due to drug-drug 
interaction. For example, Morelle and colleagues found that diclofenac interfered with tenofovir 
clearance, thereby favouring its nephrotoxicity. It is therefore suggested that NSAIDs should be 
avoided in patients receiving tenofovir (Morelle et al., 2009). In the public hospital settings, regular 
drug-utilisation reviews and consistent use of formularies and treatment protocols may enhance 
rational prescribing, and may decrease cost and prevalence of adverse reactions caused by chronic 
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plus inappropriate use of NSAIDs (Holloway & Green, 2003:2). Therefore, in this short 
communication, we report on cost-effectiveness of interchangeable use of oral NSAIDs in the 
management of pain, in adult patients, at the Tonga Hospital, Mpumalanga Province, South Africa. 
 
RESEARCH METHODS AND STUDY DESIGN  
 
This was a quantitative retrospective study using patient records as well as medicine stock control 
cards at a district hospital. Patients’ records were searched for past information with regards to the 
patterns of oral NSAIDs use in the management of pain in adult patients at Tonga Hospital. Medicine 
stock-control records were also searched for past information in regards to oral NSAIDs procurement 
practices and storage requirements in the hospital. Patients medical records included in this study 
were for patients who were 15 years and older, and who were treated with any oral NSAIDs for acute 
or chronic inflammatory conditions such as musculoskeletal pain, osteoarthritis, dental pain, low back 
pain and soft tissue injuries among others. Stock control and procurement records were included if 
they indicated 6 month old data of stock volumes and prices of each of the oral NSAIDS under study. 
Stock control and procurement records of other medicine items other than oral NSAIDs did not form 
part of this study. A pilot study was conducted whereby data were collected from 6 patient files that 
had any of the oral NSAIDs under study been prescribed within the last six months of 2013 and 2014. 
The purpose of the pilot study was to gain some background information on the patterns of each of the 
oral NSAIDs usage at Tonga Hospital, and to test the appropriateness of the proposed Data Collecting 
Instrument (DCI). The DCI for procurement and stock volumes was also tested for appropriateness by 
collecting a one month data. 
 
Ibuprofen and diclofenac use and the costs thereof in the hospital was assessed by making use of the 
“Defined Daily Dose” (DDD) as defined by WHO collaborating centre for drug statistics. The DDD’s 
of 1200mg and 150mg were used for ibuprofen and diclofenac respectively. A conversion of DDD for 
diclofenac was applied in cases whose DDD for diclofenac was 100mg, to align it to a diclofenac’s 
DDD of 150mg. A sensitivity analysis was performed on the cost of each of the oral NSAIDs in order 
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to determine what would happen if the stock volumes (quantities or stock levels) of each drug under 
study would be increased or decreased. The impact of increased or decreased cost on the quantities of 
each drug under study was also assessed. Where applicable, SPSS statistical package was used to 
assess statistical significance and unless indicated the results are presented as means with standard 
error of the mean (SEM). 
 
The study received full ethical clearance from the UKZN Research Ethics Committee (BREC REF: 
BE444/14) and from the Mpumalanga Provincial Department of Health Research and Ethics 
Committee (PHREC REF: MP_2014RP10_721). 
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RESULTS AND DISCUSSION 
 
NSAIDs usage by conditions  
The records of two hundred and eleven (104 in 2013 and 107 in 2014) patients were included in this 
study. The mean ages of all the patients who participated in our study in 2013 and 2014 was (36 ± 
1,48) and (35 ± 1,49) years respectively and there were more females than males. When the ages in 
2013 and 2014 were combined, the mean ages of males versus females were similar at 35.9 and 35.8 
years respectively and were representative of the general patient population at the Tonga Hospital. 
Most patients who presented at Tonga Hospital for pain management were suffering from minor 
bodily/joint pains (36.0%, n=76), whereas the least patients were suffering from bone fractures 
(10.9%, n=23). Our results, with regards to the prevalence of minor bodily/joint pains are in line with 
Edward and colleagues’ findings, who reported that joint pain is a common reason for consultation in 
a general practice (Edward et al., 2012).   
 
Most patients (31.3%; n=66) who were treated with ibuprofen were suffering from minor bodily/joint 
pains, whereas the least patients (1.4%; n=3) who were treated with diclofenac were suffering from 
inflammatory conditions (Figure 1). These results support population studies and World Health 
Organisation (WHO) statistics which indicate that 10–50% of individuals suffer from musculoskeletal 
disorders (Kean et al. 2005). And there were significantly (p < 0.05) more females were using 
NSAIDs (both ibuprofen and diclofenac) than males at in Tonga Hospital. And patients who were 19-
35 years were the most patients (28.4%, n=60) who were treated with ibuprofen when compared with 
patients 18 years and below (9.5%, n=20). 
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NSAID stock volumes issued  
The highest total NSAID stock volumes issued from July to December of 2013 and 2014 combined 
was ibuprofen (36978) when compared with diclofenac (11127). The stock volumes for both 
ibuprofen and diclofenac were higher in July, with 8170 for Ibuprofen and 2099 for diclofenac. 
Diclofenac stock volumes fell to their lowest (1583) in September, whereas Ibuprofen stock volumes 
fell to their lowest (4478) in December. The fall in stock volumes issued might be attributable to 
many factors including but not limited to non-delivery by the supplier, non-ordering by the pharmacy 
staff. In all instances ibuprofen stock volumes issued were higher than that of diclofenac. The demand 
for both ibuprofen and diclofenac might have been driven more by prescriber preferences and to a 
lesser extent by the patients themselves when interacting with medical officers in the consulting 
rooms. However, these results show that the demand for ibuprofen had been consistently higher than 
that of diclofenac. These findings support the study by Skúladóttir et al. (2010), who reported that in 
countries like Iceland, Denmark, Norway, and Sweden the sales volumes of ibuprofen were higher 
than that of diclofenac when the sales were measured as defined daily doses/1000 inhabitants/day. It 
means that the results of this study are in keeping with the results of studies from other countries. 
 
  





Figure 2: The patterns of stock volumes ibuprofen and diclofenac dispensed during 2013 and 2014 at 
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Figure 4: Monthly NSAID stock volumes issued 
Ibuprofen Diclofenac
Chapter 2: Manuscript 
27 
 
Acquisition costs of NSAIDs (in ZAR) and Utilisation Patterns 
The acquisition cost of ibuprofen when calculated as mean price per tablet during 2013 to 2014 was 
consistently lower, with an average price of (0.285 ZAR) when compared with diclofenac (0.995 
ZAR). The difference in the price structure of these NSAIDs is about 27.6%, making diclofenac the 
most expensive NSAID at Tonga Hospital. The average price increase of ibuprofen year on year is 
about 5.25% whereas that of diclofenac is about 8.96%. According to Smith (2000), ibuprofen is 
cheaper than diclofenac, in the same way the results of our study are in keeping with findings of other 
studies. 
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Only 0.3% of the population of Nkomazi east on average received ibuprofen treatment daily, whereas 
0.01% of the population diclofenac daily. Therefore, the population of Nkomazi east utilises more 
ibuprofen tablets than it does to diclofenac tablets. In contrast to the findings of this study with 
regards to NSAIDs utilization, Marius et al. (2007) found that despite its cardiovascular toxicity 
diclofenac (19.26 DDDs/1000 inhabitants/day) was the most commonly used NSAID when compared 
with ibuprofen (4.421 DDDs/1000 inhabitants/day) . It is apparent that the reason for the high usage 
of diclofenac (2.42/DDD, ZAR) was that it was the cheapest when compared with ibuprofen 
(5.06/DDD, ZAR), (Marius et al., 2007). 
 
The mean cost per defined daily dose was consistently lower for ibuprofen in both 2013 (0.84 ZAR) 
and 2014 (0.87 ZAR) when compared with diclofenac in 2013 (2.94 ZAR) and 2014 (3.03 ZAR). The 
frequency of prescriptions was higher for ibuprofen in 2013 (85.6%) and 2014 (79.4%) when 
compared with diclofenac in 2013 (14.4%) and 2014 (20.6%). Prescribers were consistently engaging 
in rational prescribing and were probably conscious of cost-effectiveness when prescribing more 
ibuprofen over diclofenac. The issue of acquisition costs, as shown in Table 1, has influence in the 
usage of NSAIDs in other countries as demonstrated by Vukušić et al. (2005) that diclofenac 
(2.40/DDD, ZAR) is cheaper than ibuprofen (3.31/DDD, ZAR).  
  



























Ibuprofen  400mg 
T.D.S 
0,28 x 3 = 
0,84  
 
85,6% (89)  
400mg 
T.D.S 
0,29 x 3 = 
0,87  
 
79,4% (85)  
Diclofenac  50mg 
T.D. 
0,98 x 3 = 
2,94  
 
14,4% (15)  
50mg 
T.D.S 
1,01 x 3 = 
3,03  
 
20,6% (22)  
 
Table 1:  The sensitivity analysis of mean cost/DDD showing the mean cost per DDD of ibuprofen 
and diclofenac.  
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The sensitivity analysis, as shown in Table 2, points in favour of ibuprofen over diclofenac as 
indicated when increasing or decreasing the mean price per tablet by 50% of either ibuprofen or 














 2013 2014 
Variable(S)  Mean Cost/ 
DDD (R)  
Variable(S)  Mean Cost/ 
DDD (R)  
Increasing the mean 
cost/DDD of Ibuprofen 
50% (R0,42) 1,26 50% (R0,44) 1,31 
Decreasing the mean 
cost/DDD of Ibuprofen 
50% (R0,42) 0,42 50% (R0,44) 0,44 
Increasing the mean 
cost/DDD of Diclofenac 
50% (R1,47) 4,41 50% (R1,52) 4,55 
Decreasing the mean 
cost/DDD of Diclofenac 
50% (R1,47) 1,47 50% (R1,52) 1,52 
 









This study found that the use of ibuprofen oral tablets in the management of pain at a district hospital 
is cost-effective when compared with diclofenac oral tablets. Interchangeable use of oral NSAIDs for 
pain management at a district hospital may result in pharmacoeconomic implications. The acquisition 
costs of NSAIDs in relation to the mean price per pack of oral tablets had been consistently higher for 
diclofenac than they were for ibuprofen in Tonga Hospital. There is a need to exclude diclofenac from 
the current medicine formulary in order to realise some return on the investment to pain management 
in the hospital. 
 
LIMITATIONS OF THE STUDY 
 
The study had a few limitations; firstly it was conducted in one district hospital which may limit the 
generalizability of the findings to other hospital settings. Secondly, this study did not look at the cost 
of hospitalization due to NSAIDs side effects which could have given it a comprehensive picture of 
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CHAPTER 3: SYNTHESIS & GENERAL DISCUSSION  





The objectives of the study were to determine whether the use of ibuprofen instead of diclofenac for 
oral management of pain in adults at small district hospitals is cost-effective. I also identified 
prescriber patterns or preferences between ibuprofen and diclofenac oral tablets using existing 
records. Injudicious use of oral NSAIDs for pain management may result in both health risk and 
pharmacoeconomic implications. Risks associated with NSAIDs use range from gastrointestinal, 
cardiovascular, nephrotoxicity, hepatotoxicity, to drug-drug interactions, and so on. The negative 
pharmacoeconomic implications may arise in the form of costs as a result of hospitalisation due to 
NSAIDs associated risk, as well as NSAIDs escalating market price and poor NSAID procurement 
practices.  
 
The Central Theme of this Dissertation 
The central theme, and a message running through the entire dissertation, is the cost-effectiveness of 
NSAIDs use in the management of pain at a small district hospital. We investigated retrospectively 
the comparison of cost-effective use of ibuprofen and diclofenac oral tablets by going through 
patients’ records to determine the most prescribed NSAID, as well as NSAIDs acquisition cost. Main 
attention was paid to the question of whether the use of ibuprofen instead of diclofenac for oral 
management of inflammatory conditions in adults at small district hospitals is cost-effective, since 
these two NSAIDs are used interchangeably in this hospital. Some prescribers would prefer to use 
ibuprofen instead of diclofenac and vice versa without the consideration of cost-effectiveness aspect 
of these NSAIDs. In our dissertation we proved that the use of ibuprofen oral tablets in the 
management of pain at a district hospital is cost-effective when compared with diclofenac oral tablets. 
Ibuprofen was found to be cost-effective in many respects, including its acquisition costs, mean price 
per defined daily dose, cardiovascular risk, gastrointestinal risk, and hepatotoxicity. This study, 
therefore, helped to identify and highlight what needed to be done to attain good clinical cost-
effective practice at the Tonga Hospital, and similar district hospitals. 
 




Limitations of this Study 
• Our study was limited to a small sample size because a convenience sampling technique was 
used to collect data; therefore if patients’ files were not forthcoming it meant that the sample 
size could not be increased. 
• Our findings may not be applicable to private health care settings or to large hospitals.  
• Since pharmacoeconomics is a young science, there are not many published studies that could 
have been used to support or dispute aurguments in this study. This view is shared by other 
pharmacoeconomic studies such as the ones conducted by Wynne et al. (1993) which pointed 
out that ‘‘there are only limited available data on the cost-effectiveness of NSAIDs, despite 
their wide use’’, as well as  Ahmad et al. (2013) which emphasized that ‘‘the development of 
pharmacoeconomics is at an infancy stage at the moment’’. 
 
Recommendations 
Based on our findings, it is recommended that: 
 
1. The PTC at Tonga Hospital should remove diclofenac from the Essential Medicines List, 
because it is expensive and also not the safest when compared with ibuprofen. Pharmacy 
must assess the eligibility of patients for NSAIDs especially those who have other 
comorbidities and are taking other drugs.  
 
This is necessary in order to avoid harmful drug-drug interactions such as enhanced nephrotoxicity 
which is experienced by those who are on ARV’s who are also taking NSAIDs for pain management. 
Under the current economic outlook in the country, savings that would result from implementing the 
recommendation of this study could be most welcome as part of cost-minimization strategies. 
 
2. This study attempted to address the many aspects of whether ibuprofen is cost-effective when 
compared with diclofenac oral tablets. However, further research would be required to 




determine the extent of economic impact by which NSAIDs risks cause as a result of their 
acute or chronic use.  
 
Conclusion 
Many studies have demonstrated that ibuprofen and diclofenac oral tablets have comparable efficacy, 
but differ in their safety and cost profiles. For example, ibuprofen had been found to be relatively 
cardiac safe with significant lower acquisition costs. Hawkey et al. (2000) confirms that switching 
patients to ibuprofen may be a realistic way of reducing financial and medical costs associated with 
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AQUISITION COST (IN RANDS) STOCK VOLUMES 
Ibuprofen 400mg 28’s 
Diclofenac 50mg 
21’s 
Ibuprofen 400mg 28’s Diclofenac 50mg 21’s 
1     
2     
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Ibuprofen  400mg 
T.D.S 
0,28 x 3 = 
0,84  
 
85,6% (89)  
400mg 
T.D.S 





Diclofenac  50mg 
T.D. 
0,98 x 3 = 
2,94  
 
14,4% (15)  
50mg 
T.D.S 









































APPENDIX J: Sensitivity Analysis  
 
 2013 2014 
Variable(S)  Mean Cost/ 
DDD (R)  
Variable(S)  Mean Cost/ 
DDD (R)  
Increasing the mean 
cost/DDD of Ibuprofen 
50% (R0,42) 1,26 50% (R0,44) 1,31 
Decreasing the mean 
cost/DDD of Ibuprofen 
50% (R0,42) 0,42 50% (R0,44) 0,44 
Increasing the mean 
cost/DDD of Diclofenac 
50% (R1,47) 4,41 50% (R1,52) 4,55 
Decreasing the mean 
cost/DDD of Diclofenac 
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